- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01299545
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy (PRINT)
Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy
Study Design & Objectives:
Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with a clinical follow-up between 12 and 14 weeks.
To determine the performances of the RA-INF-Dx blood test intended to aid in the identification of patients with rheumatoid arthritis who are unlikely to show an initial response to infliximab and methotrexate combination therapy evaluated according to EULAR response criteria.
Ancillary study objective:
To constitute a biocollection of samples associated with all clinical and biological data collected at inclusion and at the evaluation visit.
연구 개요
상태
정황
상세 설명
The RA-INF-Dx test is a non invasive in vitro blood test intended to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.
The RA-INF-Dx test is indicated for use in patients:
- 18 years of age or older,
- Eligible for a first line biologic therapy with infliximab. The RA-INF-Dx test is indicated for use by rheumatologists as a biological basis for guiding infliximab treatment prior to its initiation.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Bucharest, 루마니아
- Location n° 19
-
Bucharest, 루마니아
- Location n°20
-
Bucharest, 루마니아
- Location n°22
-
Bucharest, 루마니아
- Location n°23
-
Cluj Napoca, 루마니아
- Location n°21
-
Iasi, 루마니아
- Location n°24
-
Iasi, 루마니아
- Location n°26
-
Timisoara, 루마니아
- Location n°18
-
-
-
-
-
Kaunas, 리투아니아
- Location n°27
-
Klaipeda, 리투아니아
- Location n°29
-
Panevezys, 리투아니아
- Location n°30
-
Vilnius, 리투아니아
- Location n°28
-
-
-
-
-
Malaga, 스페인
- Location n°3
-
Oviedo, 스페인
- Location n°5
-
-
-
-
-
Banska Bystrica, 슬로바키아
- Location n°12
-
Piestany, 슬로바키아
- Location n°11
-
-
-
-
-
Messina, 이탈리아
- Location n°15
-
Milano, 이탈리아
- Location n°16
-
Pisa, 이탈리아
- Location n°17
-
-
-
-
-
Mississauga - Chow, 캐나다
- Location n°31
-
Ontario, 캐나다
- Location n°36
-
Rimouski, 캐나다
- Location n°34
-
Saskatchewan, 캐나다
- Location n°33
-
Toronto, 캐나다
- Location n°35
-
-
-
-
-
Amiens, 프랑스
- Location n°41
-
Bobigny, 프랑스
- Location n°13
-
Dreux, 프랑스
- Location n°39
-
Grenoble, 프랑스
- Location n°14
-
Meaux, 프랑스
- Location n°40
-
Paris, 프랑스
- Location n°25
-
Paris (Hop Bichat), 프랑스
- Location n°37
-
Strasbourg, 프랑스
- Location n°38
-
-
-
-
-
Budapest, 헝가리
- Location n°6
-
Budapest, 헝가리
- Location n°8
-
Debrecen, 헝가리
- Location n°7
-
Eger, 헝가리
- Location n°10
-
Kistarcsa, 헝가리
- Location n°9
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
Diagnosis of Rheumatoid Arthritis
Patient with a confirmed Rheumatoid Arthritis according the American College of Rheumatology (ACR) classification criteria.
Disease Activity
Patient with a DAS28 greater than 3.2.
Treatment
- Patient eligible for a first line TNFα blocking agent treatment with infliximab according to the "Summary of Product Characteristics",
- Patient refractory to treatment with at least one classical DMARDs (one of which has to be MTX) prescribed according to the international recommendations, i.e. for at least 12 weeks at the maximal tolerated dose prior to infliximab treatment and with doses which must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy (patients may be included if they have undergone a wash-out period using cholestyramine or equivalent subsequent to leflunomide treatment),
Use of oral steroids (≤ 10mg/day of prednisone or equivalent dose of another molecule) and/or NSAIDs will be permitted; doses must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy,
Other criteria
- Patient (male or female) at 18 years of age or older at inclusion,
- Negative β-HCG pregnancy test, when appropriate according to the patient's age and contraceptive method,
- Informed consent signed.
Exclusion Criteria:
- Patient having received previous courses of other biologic therapy (TNF blocking agents, anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in development),
- Patient non eligible to infliximab therapy according to the "Summary of Product Characteristics",
- Patient with clinically significant, severe and uncontrolled infectious diseases,
- Patient with symptoms of a significant somatic or psychiatric/mental illness,
- Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic Lupus Erythematosus, vasculitis, uncontrolled asthma, etc...),
- Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic, gastro-intestinal conditions, which, in the opinion of the investigator, may interfere with the study,
- Pregnancy,
- Patient that is participating in a clinical trial or that participated in a previous one within 10 weeks prior to study entry.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
a single group of patients -200 expected
polyarthrite rhumatoid patients
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
To determine the performances of the RA-INF-Dx test to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.
기간: Performed at inclusion : blood samples will be taken before the infliximab infusion.
|
Statistical relationship between the RA-INF-Dx blood test results and the non-response (evaluated according to EULAR criteria) to infliximab and methotrexate combination therapy will be analyzed.
|
Performed at inclusion : blood samples will be taken before the infliximab infusion.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Non-response to infliximab and methotrexate combination therapy based on American College of Rheumatology (ACR) criteria
기간: at the time of the first response evaluation (between the 12th and the 14th week)
|
A statistical analysis will be performed in order to evaluate the predictive performances of the test validated in the study primary objective in relation to the non-response to infliximab and methotrexate combination therapy evaluated according to ACR criteria.
|
at the time of the first response evaluation (between the 12th and the 14th week)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sara MARSAL, MD, University Hospital Val d'Hebron (Barcelona, Spain)
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .